SEA Health Tech Investment Insights

Digital Health Indonesia's market and regulatory landscape is favorable to digital health-tech Patient rights are guaranteed by several laws, including the right to confidentiality, to information about treatment and costs, to give consent to any procedures and not to be treated negligently (see Law no. 36 of 2009 from the Ministry of Communication and Informatics). Pharmaceuticals The National Agency for Food and Drug Control supervises food and drug in Indonesia. A large volume of drugs are produced locally and need to meet the requirements of Good Manufacturing Practice (GMP) 95% of the basic ingredients are imported MoH primarily uses generics to supply the public sector (60%) Medical Equipment . Indonesia imports 97% of medical devices. . Regulations details: https://www.who.int/medical_devices/countries/r egulations/idn.pdf?ua=1 SEA research in Medical Equipment / MedTech is dominated by Singapore who invests . The pharmaceutical and medical equipment advancements are currently dominated by Singapore in SEA thanks to favorable infrastructure, stable legal environment and large investments offered by the authorities (see the 2019 budget with S$1 billion worth of measures to help businesses build 'deep' capabilities Sources: WHO (The Republic of Indonesia - Health System Review), World Bank, DLA Piper, Expert interviews . In April 2020, Reuters wrote that "Indonesia leans on Health Tech startups to cope with virus surge" INSEAD Experts highlighted that the digital health space is where most of the local new ventures will come from, with already the emergence of local 'winners' such as Halodoc and Alodokter. The Indonesian Healthtech Association offers a comprehensive list of stakeholders: https://healthtech.id/members/ Introduction of measures to support SMEs, e.g. "Let SMEs Sell Online" in 2018, with a goal of 8m SMEs selling their products via the internet by 2020. In Indonesia, there is still no general law on data protection 31

View entire presentation